Financials data is unavailable for this security.
View more
Year on year Cathay Biotech Inc 's revenues fell -13.39% from 2.44bn to 2.11bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 553.27m to 366.52m, a -33.75% decrease.
| Gross margin | 28.53% |
|---|---|
| Net profit margin | 15.35% |
| Operating margin | 17.23% |
| Return on assets | 2.11% |
|---|---|
| Return on equity | 3.33% |
| Return on investment | 3.24% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Cathay Biotech Inc fell by 1.21bn. However, the company earned 569.45m from its operations for a Cash Flow Margin of 26.93%. In addition the company used 1.56bn on investing activities and also paid 262.16m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 19.34 |
|---|---|
| Tangible book value per share | 18.15 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.78 |
|---|---|
| Quick ratio | 2.24 |
| Total debt/total equity | 0.1162 |
|---|---|
| Total debt/total capital | 0.0809 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share increased 5.56% while earnings per share excluding extraordinary items fell by -33.68%. The positive trend in dividend payments is noteworthy since only some companies in the Chemical Manufacturing industry pay a dividend. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.37% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 29.68% |
| EPS growth(5 years) | -7.54 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -18.62 |
More ▼
